A Phase I Study of BMS-936558 in Patients with Relapsed or Refractory Hematologic Cancers

Protocol
12-142
Full Title
A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed- Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy
Purpose

The purpose of this study is to find the highest dose of an investigational drug called BMS-936558 in patients with multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, or chronic myelogenous leukemia that persists or has returned despite prior therapy. BMS-936558 boosts the body’s immune system by targeting a protein on white blood cells called PD-1.

PD-1 normally maintains the balance of the immune system by shutting it down at the right time. Some cancers take advantage of this shut-down mechanism by activating PD-1, enabling them to escape attack by the body’s white blood cells. BMS-936558 binds to and inactivates PD-1, enhancing the body’s ability to detect and destroy cancer cells.

Investigator
Pictured: Alexander Lesokhin
Alexander M. Lesokhin - Physician Profile
Co-Investigators
Craig H. Moskowitz, MD -- Clinical Director, Division of Hematologic Oncology
Craig H. Moskowitz - Physician Profile
Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, or chronic myelogenous leukemia that persists or has returned despite prior therapy.
  • Patients must have had at least one prior regimen of chemotherapy.
  • At least 3 weeks must have passed since the completion of chemotherapy and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Alexander Lesokhin at 212-639-3069.

Disease(s)
Hematology: Multiple Myeloma
Leukemia
Leukemia: Chronic Myelocytic Leukemia
Lymphoma
Lymphoma: Hodgkin's Disease
Lymphoma: Non-Hodgkin's Lymphoma
Locations
ClinicalTrials.gov
Related Diseases

Clinical Trials

Clinical trials can offer you access to a new, experimental treatment before it is available to most patients. Joining a clinical trial is also a way to make a valuable contribution toward the fight against cancer.